Folate targeting enables durable and specific antitumor responses from a therapeutically null tubulysin B analogue

Cancer Research

Volumn 68, Issue 23, 2008, Pages 9839-9844

  Leamon, Christopher P ^a,b   Reddy, Joseph A ^a   Vetzel, Marilynn ^a   Dorton, Ryan ^a   Westrick, Elaine ^a   Parker, Nikki ^a   Wang, Yu ^a   Vlahov, Iontcho ^a  

^a Endocyte Inc   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EC 0305; FOLATE RECEPTOR; FOLIC ACID; HYBRID PROTEIN; TUBULYSIN B DERIVATIVE; TUBULYSIN B HYDRAZIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONCENTRATION RESPONSE; CONJUGATE; CONTROLLED STUDY; DRUG POTENCY; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LIGAND BINDING; MICROTUBULE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT DURATION; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CARRIER PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; ETHYLENEDIAMINES; FEMALE; FLUORESCEIN; FOLIC ACID; HUMANS; KB CELLS; MICE; MICE, INBRED BALB C; MICE, NUDE; OLIGOPEPTIDES; RECEPTORS, CELL SURFACE; SUBSTRATE SPECIFICITY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 57149087269     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-2341     Document Type: Article

References (36)

1. Reddy JA, Dorton R, Westrick E, et al. Preclinical evaluation of EC145, a folate-vinca alkaloid conjugate. Cancer Res 2007;67:4434-42.
2. Reddy JA, Westrick E, Santhapuram HK, et al. Folate receptor-specific antitumor activity of EC131, a folate-maytansinoid conjugate. Cancer Res 2007;67:6376-82.
3. Henry MD, Wen S, Silva MD, Chandra S, Milton M, Worland PJ. A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer. Cancer Res 2004;64:7995-8001.
4. + multiple myeloma cells. Cancer Res 2004;64:4629-36.
5. Engel JB, Schally AV, Halmos G, Baker B, Nagy A, Keller G. Targeted therapy with a cytotoxic somatostatin analog, AN-238, inhibits growth of human experimental endometrial carcinomas expressing multidrug resistance protein MDR-1. Cancer 2005;104:1312-21.
6. Cao Q, Li ZB, Chen K, et al. Evaluation of biodistribution and anti-tumor effect of a dimeric RGD peptide-paclitaxel conjugate in mice with breast cancer. Eur J Nucl Med Mol Imaging 2008;35:1489-98.
7. Gilbert CW, McGowan EB, Seery GB, Black KS, Pegram MD. Targeted prodrug treatment of HER-2-positive breast tumor cells using trastuzumab and paclitaxel linked by A-Z-CINN Linker. J Exp Ther Oncol 2003;3:27-35.
8. Reddy JA, Allagadda VM, Leamon CP. Targeting therapeutic and imaging agents to folate receptor positive tumors. Curr Pharm Biotechnol 2005;6:131-50.
9. Reddy JA, Low PS. Folate-mediated targeting of therapeutic and imaging agents to cancers. Crit Rev Ther Drug Carrier Syst 1998;15:587-627.
10. Leamon CP, Low PS. Folate-mediated targeting: from diagnostics to drug and gene delivery. Drug Discov Today 2001;6:44-51.
11. Reddy JA, Leamon CP, Low PS. Folate-mediated delivery of protein and peptide drugs into tumors. In: Torchilin V, editor. Delivery of protein and peptide drugs in cancer. London: World Scientific/Imperial College Press; 2006. p. 183-204.
12. Weitman SD, Lark RH, Coney LR, et al. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res 1992;52:3396-401.
13. Ross JF, Chaudhuri PK, Ratnam M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer 1994;73:2432-43.
14. Toffoli G, Cernigoi C, Russo A, Gallo A, Bagnoli M, Boiocchi M. Overexpression of folate binding protein in ovarian cancers. Int J Cancer 1997;74:193-8.
15. Parker N, Turk MJ, Westrick E, Lewis JD, Low PS, Leamon CP. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem 2005;338:284-93.
16. Leamon CP, Low PS. Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis. Proc Natl Acad Sci U S A 1991;88:5572-6.
17. Leamon CP, Low PS. Membrane folate-binding proteins are responsible for folate-protein conjugate endocytosis into cultured cells. Biochem J 1993;291:855-60.
18. Rund LA, Cho BK, Manning TC, Holler PD, Roy EJ, Kranz DM. Bispecific agents target endogenous murine T cells against human tumor xenografts. Int J Cancer 1999;83:141-9.
19. Lu Y, Low PS. Folate targeting of haptens to cancer cell surfaces mediates immunotherapy of syngeneic murine tumors. Cancer Immunol Immunother 2002;51:153-62.
20. Lee RJ, Low PS. Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. J Biol Chem 1994;269:3198-204.
21. Reddy JA, Abburi C, Hofland H, et al. Folate-targeted, cationic liposome-mediated gene transfer into disseminated peritoneal tumors. Gene Ther 2002;9:1542-50.
22. Reddy JA, Xu LC, Parker N, Vetzel M, Leamon CP. Preclinical evaluation of (99m)Tc-EC20 for imaging folate receptor-positive tumors. J Nucl Med 2004;45:857-66.
23. Ladino CA, Chari RVJ, Bourret LA, Kedersha NL, Goldmacher VS. Folatemaytansinoids: target-selective drugs of low molecular weight. Int J Cancer 1997;73:859-64.
24. Reddy JA, Westrick E, Vlahov I, Howard SJ, Santhapuram HK, Leamon CP. Folate receptor specific anti-tumor activity of folate-mitomycin conjugates. Cancer Chemother Pharmacol 2006;58:229-36.
25. Kaur G, Hollingshead M, Holbeck S, et al. Biological evaluation of tubulysin A: a potential anticancer and antiangiogenic natural product. Biochem J 2006;396:235-42.
26. Steinmetz H, Glaser N, Herdtweck E, Sasse F, Reichenbach H, Hofle G. Isolation, crystal and solution structure determination, and biosynthesis of tubulysins-powerful inhibitors of tubulin polymerization from myxobacteria. Angew Chem Int Ed Engl 2004;43:4888-92.
27. Ma L, Gunawan P, Jensen GS, et al. Polymer-tubulysin nanoparticles as antitumor agents. NanoBio 2007: 2nd International Congress of Nanobiotechnology & Nanomedicine; San Francisco; 2007.
28. Leamon CP, Parker MA, Vlahov IR, et al. Synthesis and biological evaluation of EC20: a new folate-derived 99mTc-based radiopharmaceutical. Bioconjug Chem 2002;13:1200-10.
29. Leamon CP, Reddy JA, Vlahov IR, et al. Preclinical antitumor activity of a novel folate-targeted dual drug conjugate. Mol Pharm 2007;4:659-67.
30. Mathias CJ, Wang S, Lee RJ, Waters DJ, Low PS, Green MA. Tumor-selective radiopharmaceutical targeting via receptor-mediated endocytosis of gallium-67-deferoxamine-folate. J Nucl Med 1996;37:1003-8.
31. Leamon CP, Reddy JA, Vlahov IR, et al. Comparative preclinical activity of the folate-targeted vinca alkaloid conjugates EC140 and EC145. Int J Cancer 2007;121:1585-92.
32. Sausville E, LoRusso P, Quinn M, et al. A phase I study of EC145 administered weeks 1 and 3 of a 4-week cycle in patients with refractory solid tumors. J Clin Oncol 2007;25:2577.
33. Leamon CP, Reddy JA, Vlahov IR, Kleindl PJ, Vetzel M, Westrick E. Synthesis and biological evaluation of EC140: a novel folate-targeted vinca alkaloid conjugate. Bioconjug Chem 2006;17:1226-32.
34. Leamon CP, Reddy JA, Vlahov IR, et al. Synthesis and biological evaluation of EC72: a new folate-targeted chemotherapeutic. Bioconjug Chem 2005;16:803-11.
35. Leamon CP. Folate-targeted chemotherapy: in vitro and in vivo activity of EC72. Proc Am Assoc Cancer Res 2003;44:Abstract # 2627.
36. Covello KL, Flefleh C, Menard K, et al. Preclinical pharmacology of epothilone-folate conjugate BMS-753493, a tumor-targeting agent selected for clinical development. Proceedings of the 99th Annual Meeting of AACR; 2008; San Diego, CA. Abstract #2326.